INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA • US45781K2042

1.65 USD
-0.07 (-3.79%)
Last: Mar 2, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall IPHA gets a fundamental rating of 2 out of 10. We evaluated IPHA against 520 industry peers in the Biotechnology industry. Both the profitability and financial health of IPHA have multiple concerns. IPHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year IPHA has reported negative net income.
  • In the past year IPHA has reported a negative cash flow from operations.
  • In the past 5 years IPHA always reported negative net income.
  • In the past 5 years IPHA always reported negative operating cash flow.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • IPHA has a Return On Assets (-49.55%) which is in line with its industry peers.
  • IPHA has a Return On Equity of -895.24%. This is in the lower half of the industry: IPHA underperforms 79.23% of its industry peers.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • With a decent Gross Margin value of 49.52%, IPHA is doing good in the industry, outperforming 75.38% of the companies in the same industry.
  • IPHA's Gross Margin has declined in the last couple of years.
  • IPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IPHA has more shares outstanding
  • IPHA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, IPHA has an improved debt to assets ratio.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • IPHA has an Altman-Z score of -6.50. This is a bad value and indicates that IPHA is not financially healthy and even has some risk of bankruptcy.
  • IPHA's Altman-Z score of -6.50 is on the low side compared to the rest of the industry. IPHA is outperformed by 64.81% of its industry peers.
  • IPHA has a Debt/Equity ratio of 3.52. This is a high value indicating a heavy dependency on external financing.
  • IPHA has a Debt to Equity ratio of 3.52. This is amonst the worse of the industry: IPHA underperforms 80.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC7.02%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IPHA has a Current Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
  • IPHA has a worse Current ratio (2.21) than 74.23% of its industry peers.
  • A Quick Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.21, IPHA is doing worse than 72.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for IPHA have decreased strongly by -30.42% in the last year.
  • Looking at the last year, IPHA shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.
  • The Revenue for IPHA have been decreasing by -28.80% on average. This is quite bad
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

  • IPHA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.15% yearly.
  • IPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.95% yearly.
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue Next Year-22.57%
Revenue Next 2Y-12.86%
Revenue Next 3Y-22.02%
Revenue Next 5Y41.95%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as IPHA's earnings are expected to decrease with -19.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (3/2/2026, 8:00:02 PM)

1.65

-0.07 (-3.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners9.46%
Inst Owner Change238.5%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap154.61M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts82.5
Price Target7.41 (349.09%)
Short Float %0.19%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.68%
PT rev (3m)30.64%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)1.64%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)4.93%
Revenue NY rev (3m)4.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.03
P/FCF N/A
P/OCF N/A
P/B 25.69
P/tB 25.69
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.07
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.5
F-Score2
WACC7.02%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-22.57%
Revenue Next 2Y-12.86%
Revenue Next 3Y-22.02%
Revenue Next 5Y41.95%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.82%
EBIT Next 3Y95.79%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPHA.


Can you provide the valuation status for INNATE PHARMA SA-SPONS ADR?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.


What is the profitability of IPHA stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.


What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.